Head of QA
Hubro Therapeutics
- Frist 13.1.2022
- Ansettelsesform Fast
HUBRO THERAPEUTICS IS LOOKING FOR HEAD OF QA
Hubro Therapeutics is currently seeking for Head of QA who will take an active role in the further development of our products and the company.
Main Responsibilities
As Head of QA, you will provide quality expertise for our company in the development of our products in preclinical and clinical phases and to build quality systems supporting our product development within CMC, preclinical and clinical.
You will be responsible for
· To ensure acceptable compliance with EU and US GxP (GMP, GCP GDP, GLP etc) in product development projects
· To develop, implement and maintain the Quality Management System (QMS)
· To lead and coordinate quality audits and inspections
· To secure QA oversight and evaluation of suppliers, service providers and contract manufacturing organisations
· Deviation handling
· Change Control
Skills & Competencies
· PhD or a MSc in pharmacy, chemistry, biotechnology or similar
· Solid knowledge about quality standards like GMP, GLP, GCP, ICH etc.
· Experience from QA work in pharmaceutical or biotech industry and R&D
· Strong interpersonal and management skills and with the ability to build trustful relationships
· Strong English communication skills
· Management experience
Beneficial Requirements & Qualifications
· Adaptability
· Ability to work independently and at the same time be a good team player
· Ability to find solution to complex challenges.
We can offer varied and exciting work in an innovative and dynamic biotech company. We promise you will develop professionally with challenging tasks in a growing company, as you participate in the development of novel cancer treatments. Some international travel and participation / presentation at science conferences and events can be expected.
Please send your CV and application in English to the email listen in the contact information as soon as possible and latest by January 13th, 2022.
For additional information please contact CTO Berit Iversen via e-mail as above or phone: +47 98 23 84 93 or CEO Jon Amund Eriksen on phone +47 95 08 59 14.
All applications will be treated confidentially.
Om arbeidsgiveren
Our lead candidate vaccine is FMPV-1 targets frameshift mutation in the transforming growth factor beta receptor 2 (TGFbR2) gene, frequently present in MSI-colorectal and stomach cancer as well as in hereditary colorectal cancer.
- Sektor: Privat
- Sted: Ullernchausseen 64, 0379 Oslo
- Bransje: Farmasi og legemiddel, Forskning, utdanning og vitenskap
- Stillingsfunksjon: Dokumentasjon, Kvalitetssikring, Prosjektledelse
Nøkkelord
QA
Annonseinformasjon
- FINN-kode 241462085
- Sist endret